Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Montelukast Sodium Intermediate. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN112724082B details a cost-effective copper-catalyzed route for montelukast intermediates, offering superior purity and supply chain stability for global pharmaceutical manufacturers.
Patent CN106928136B details graphene palladium cobalt catalysis for montelukast intermediate. Offers high yield and chiral selectivity for reliable pharmaceutical intermediate supply chains.
Patent CN103073492A details a green Ru-catalyzed transfer hydrogenation for Montelukast intermediates, offering significant cost reduction and supply chain reliability.
Novel nucleophilic substitution route for Montelukast intermediate. High optical purity, mild conditions, cost-effective manufacturing for global supply chains.
Advanced preparation process for Montelukast sodium intermediate via efficient sulfonylation and thiourea displacement. Delivers high purity and scalable manufacturing solutions.
Patent CN112624921A reveals a novel Grignard-based synthesis for 1-hydroxymethyl cyclopropyl acetic acid, offering significant cost reduction and safety improvements for Montelukast manufacturing.
Discover the novel 4-step synthesis of Montelukast Sodium intermediate via patent CN115710221A. Achieve high purity, reduced costs, and scalable supply chain solutions.
Novel 2-step synthesis of Montelukast intermediate via Wittig and Pd-coupling. Reduces cost and steps for API manufacturing.